Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is -56.30% vs 26.75% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is -34.39% vs 261.78% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 108.74% vs 1.50% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -48.35% vs 320.68% in Mar 2024
Compare Profit and Loss Results of Shukra Pharma.
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
32.00
667.00
-635.00
-95.20%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
32.00
667.00
-635.00
-95.20%
Expenditure (Ex Depriciation)
Stock Adjustments
-3.00
6.00
-9.00
-150.00%
Raw Materials Consumed
11.00
339.00
-328.00
-96.76%
Power & Fuel Cost
0.00
9.00
-9.00
-100.00%
Employee Cost
6.00
99.00
-93.00
-93.94%
Operating Expenses
0.00
15.00
-15.00
-100.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
0.00
62.00
-62.00
-100.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
28.00
-28.00
-100.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
19.00
575.00
-556.00
-96.70%
Operating Profit (PBDIT) excl Other Income
12.00
91.00
-79.00
-86.81%
Other Income
4.00
36.00
-32.00
-88.89%
Operating Profit (PBDIT)
16.00
127.00
-111.00
-87.40%
Interest
0.00
6.00
-6.00
-100.00%
Profit before Depriciation and Tax
16.00
121.00
-105.00
-86.78%
Depreciation
3.00
27.00
-24.00
-88.89%
Profit Before Taxation & Exceptional Items
13.00
94.00
-81.00
-86.17%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
13.00
94.00
-81.00
-86.17%
Provision for Tax
3.00
25.00
-22.00
-88.00%
Profit After Tax
9.00
68.00
-59.00
-86.76%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
37.00
892.00
-855.00
-95.85%
Profit Available for appropriations
47.00
961.00
-914.00
-95.11%
Appropriations
47.00
961.00
-914.00
-95.11%
Equity Dividend (%)
1%
50%
-49.00
Earnings Per Share
0.22
6.56
-6.34
-96.65%
Profit And Loss - Net Sales
Net Sales 32.59 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -56.30% vs 26.75% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 12.73 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -34.39% vs 261.78% in Mar 2024
Profit And Loss - Interest
Interest 0.59 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 108.74% vs 1.50% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 9.58 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -48.35% vs 320.68% in Mar 2024






